Real-World Use of Pacritinib in Myelofibrosis: Results From the TriNetX Analysis on Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Platelets ≥50 &#215; 109/L at Initiation (TRIPAC)

Jakafi (ruxolitinib) - Incyte

Vonjo (pacritinib) - SOBI

https://www.sciencedirect.com/science/article/abs/pii/S2152265026024055

Ghaith Abu-Zeinah MD 1; Alex Coltoff MD 2; Erick Moyneur MA 3; Katherine Dea MSc 3; Michael Marrone PhD,MPH 4; Sara Bruce Wirta PhD 5; Faizan Sattar PharmD 4; Michael Vredenburg PhD 4; Andrew Srisuwananukorn MD 6

Sep 1, 2026